Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McKesson/Celesio Deal Targets Generics Purchasing Synergies

This article was originally published in The Pink Sheet Daily

Executive Summary

McKesson believes its acquisition of European drug wholesaler Celesio will result in $275 million to $325 million in synergies four years out, and much of the savings will be achieved through generic drug purchasing.

You may also be interested in...



Walgreens Grows Internationally With Alliance Boots Stake

Walgreens is acquiring 45% of the U.K.-based international retailer and wholesaler Alliance Boots, which runs pharmacies in 11 countries, with an option to acquire the entire firm in three years.

Business News, In Brief

Companies talk drug launches and pipelines during first quarter earnings calls in May; with some having more success than others.

Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel